Abstract 11629: Multicenter Development and Validation of a Machine Learning Risk Model to Predict Right Ventricular Failure Following Mechanical Circulatory Support: The STOP-RVF Score

Christos P KyriakopoulosIosif TalebNaila IjazZachary DemertzisAdithya PeruriOmar Wever-PinzonAntigone G KoliopoulouMichael J BoniosThomas C HanffElizabeth DranowTheodoros V GiannouchosKonstantinos SiderisMarisca NelsonAshley ElmerDaniel TangHassan NemehJosef StehlikJames C FangCraig H SelzmanRami AlharethiWilliam CaineJennifer CowgerPalak ShahStavros G DrakosUtah Transplantation Affiliated Hosps (UTAH) Cardiac Transplant Program (Univ of Utah Health and Sch of Medicine,Intermountain Med Cntr,George E. Wahlen Dept of Veterans Affairs Med Cntr),Salt Lake City,UTHeart Failure,Mechanical Circulatory Support & Transplant,Inova Heart & Vascular Institute,Falls Church,VAHenry Ford Med Cntr,Detroit,MI
DOI: https://doi.org/10.1161/circ.146.suppl_1.11629
IF: 37.8
2022-11-01
Circulation
Abstract:Circulation, Volume 146, Issue Suppl_1, Page A11629-A11629, November 8, 2022. Introduction:Existing models predicting right ventricular failure (RVF) after durable left ventricular assist device (LVAD) support are limited due to lack of multicenter validation, absence of intraoperative characteristics, and marginal predictive power. We sought to derive and validate a risk model to predict post-LVAD RVF.Methods:Advanced heart failure (HF) patients (N=798) requiring continuous-flow LVAD were enrolled at the Utah Transplant Affiliated Hospitals (n=477), Inova Heart & Vascular Institute (n=183), and Henry Ford Medical Center (n=138). Baseline clinical and intraoperative characteristics were recorded. The primary outcome was RVF incidence, defined as the need for right VAD (RVAD) or intravenous inotropes for >14 days. Bootstrap imputation and lasso variable selection were used to derive a predictive model which was then validated. A risk calculator was developed classifying patients into risk groups, and survival was compared.Results:Patients were predominantly white (72%), males (84%), aged 56±13 years. Patients in the RVF and non-RVF groups were comparable in terms of sex, age, and LVAD indication, while RVF patients more commonly had a history of systemic hypertension, non-ischemic cardiomyopathy, lower INTERMACS profiles, and more commonly required inotropic or temporary circulatory support pre-LVAD. Overall, 193 (24.2%) patients developed RVF with 109 (56.5%) requiring inotropes and 84 (43.5%) an RVAD. Multivariable predictors for RVF are shown in theFigureand achieved a c-statistic of 0.74 (95% CI: 0.70-0.78). Inclusion of intraoperative characteristics did not improve model performance. Cumulative survival was higher in the minimal risk group compared to low, moderate, and high.Conclusions:The STOP-RVF calculator effectively stratifies the risk for RVF after LVAD support by implementing routinely collected clinical data. It could impact patient selection and peri-operative management of advanced HF patients.
cardiac & cardiovascular systems,peripheral vascular disease
What problem does this paper attempt to address?